论文部分内容阅读
目的:观察培美曲赛单药治疗老年中晚期非小细胞肺癌的疗效和不良反应。方法:总结分析于本院诊治2008～2009年26例老年(70～81岁)ⅢA-Ⅳ期非小细胞肺癌患者接受培美曲赛单药化疗2周期后行临床疗效和不良反应。结果:完全缓解(CR)0例,部分缓解(PR)6例,总有效率为23.08%,疾病稳定(SD)11例,疾病进展(PD)9例。全组毒性不良反应较轻,主要为骨髓抑制,可耐受。结论:培美曲赛治疗老年非小细胞肺癌疗效较好,不良反应轻,可明显改善老年患者生存质量。
Objective: To observe the efficacy and adverse reactions of pemetrexed monotherapy in the treatment of advanced non-small cell lung cancer in the elderly. Methods: To summarize and analyze the clinical efficacy and side effects of pemetrexed monotherapy in 26 patients aged from 70 to 81 years with non-small cell lung cancer of stage ⅡA-Ⅳ between 2008 and 2009 in our hospital. Results: There were 0 cases of complete remission (CR) and 6 cases of partial remission (PR). The total effective rate was 23.08%, 11 cases of stable disease (SD) and 9 cases of disease progression (PD). The whole group of toxic adverse reactions, mainly for bone marrow suppression, tolerable. Conclusion: Pemeimeixai treatment of elderly patients with non-small cell lung cancer better efficacy, mild adverse reactions, can significantly improve the quality of life in elderly patients.